<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03080519</url>
  </required_header>
  <id_info>
    <org_study_id>2017-ZX-0214</org_study_id>
    <nct_id>NCT03080519</nct_id>
  </id_info>
  <brief_title>Endovascular Therapy for Renal Artery Stenosis in China</brief_title>
  <acronym>ETRAS-China</acronym>
  <official_title>A Multicenter Registry of Endovascular Therapy for Renal Artery Stenosis in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences, Fuwai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences, Fuwai Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter prospective registry planned to recruit more than 5 000 patients with renal
      artery stenosis was carried out in China. This primary purpose of this study was to evaluate
      the safety and efficacy of renal artery revascularization in the real world. The secondary
      purpose was to investigate the etiologic distribution of renal artery stenosis and optimize
      the indications for renal artery revascularization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently,the endovascular therapy of renal artery stenosis (especially atherosclerotic)
      remains in dispute. Some randomized control trials published in recent years (including
      ASTRAL and CORAL trials) showed the lack of additional benefit for renal artery
      revascularization compared with sole medical therapy. However,these randomized control trials
      presented a number of limitations including low numbers of patients and non-stringent
      inclusion criteria. Given clinical medical practice entering the era of big data, the
      large-sample real-word studies would be more objective to answer some pending issues of
      randomized controlled trial.Therefore,a multicenter prospective registry planned to recruit
      more than 5 000 patients with renal artery stenosis was carried out. This primary purpose of
      this study was to evaluate the safety and efficacy of renal artery revascularization in the
      real world. The secondary purpose was to investigate the etiologic distribution of renal
      artery stenosis and optimize the indications for renal artery revascularization.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2017</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Intervational Therapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy：Change in blood pressure compared to baseline</measure>
    <time_frame>Measured at 1 month and every 6 months thereafter from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Change in estimated glomerular filtration rate compared to baseline</measure>
    <time_frame>Measured at 1 month and every 6 months thereafter from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device or procedure related acute adverse events (renal artery dissection,renal artery perforation,bleeding,and etc.)</measure>
    <time_frame>Perioperative period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of major adverse event (cardiovascular or renal death,myocardial infarction,hospitalization for congestive heart failure, stroke, and renal failure)</measure>
    <time_frame>Measured at 1 month and every 6 months thereafter from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of renal artery restenosis(&gt;50%)</measure>
    <time_frame>Measured every 6 months from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Renal Artery Obstruction</condition>
  <condition>Hypertension, Renovascular</condition>
  <arm_group>
    <arm_group_label>Endovascular Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renal artery revascularization</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endovascular Therapy</intervention_name>
    <description>Balloon angioplasty and stenting for renal artery stenosis</description>
    <arm_group_label>Endovascular Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 14 at the time of informed consent

          2. Diameter reduction of renal artery or main branch of renal artery≥ 60%,and ≥2 of four
             following conditions met:1)systolic hyperemic pressure gradient ＞20 mm Hg,2)captopril
             renoscitigraphy positive in the lesion side

             ,3)renin-angiotensin-aldosterone system significantly activated and 4)severe reduction
             (＞25%) of glomendar filtration rate in the lesion side

          3. office systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg
             while receiving 3 antihypertensive drugs,or office systolic blood pressure ≥160 mmHg
             and/or diastolic blood pressure ≥100 mmHg without antihypertensive drugs

          4. Serum creatinine level＜264umol/L

          5. Length of ipsilateral kidney ≥7.0 cm and glomendar filtration rate ≥10 ml／min

          6. Urine protein ＜2+

        Exclusion Criteria:

          1. Unable to provide informed consent

          2. Unstable condition and unable to tolerate interventional therapy

          3. intolerance to antiplatelet drugs or contrast medium

          4. vascular anatomy not suitable for endovascular therapy

          5. Pregnant, nursing, or planning to be pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiongjing Jiang, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiongjing Jiang, MD</last_name>
    <phone>86-1088322385</phone>
    <email>jxj103@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hui Dong, MD</last_name>
    <phone>86-1088322387</phone>
    <email>donghui666@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Renhe Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>010</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiongjing Jiang, MD</last_name>
      <phone>86-1088322385</phone>
      <email>jxj103@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Daping Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>023</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhigang Zhao, MD</last_name>
      <phone>86-023-68811229</phone>
      <email>zhaozgsir@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lanzhou University Second Hospital</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <zip>0931</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jing Yu, MD</last_name>
      <phone>86-0931-8942262</phone>
      <email>yujing2304@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jianfang Luo, MD</last_name>
      <phone>86-020-83827812</phone>
      <email>henryjfl@tom.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Eighth Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>0755</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nan Jia, MD</last_name>
      <phone>86-0755-83982222</phone>
      <email>jiananchina@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hongqi Hospital</name>
      <address>
        <city>Mudanjiang</city>
        <state>Heilongjiang</state>
        <zip>0453</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tongqing Lu, MD</last_name>
      <phone>86-0453-6224739</phone>
      <email>lutongqing@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>0791</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zeqi Zheng, MD</last_name>
      <phone>86-0791-88692748</phone>
      <email>zeqizheng@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>0791</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ping Li, MD</last_name>
      <phone>86-0791-86297662</phone>
      <email>lipingsydney@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The General Hospital of Shenyang Military</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>024</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaozeng Wang, MD</last_name>
      <phone>86-024-28886666</phone>
      <email>wxiaozeng@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital, Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jianzhong Xu, MD</last_name>
      <phone>86-021-64370045</phone>
      <email>jianzhongxv@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanxi Cardiovascular Hospital</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>0351</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bin Yang, MD</last_name>
      <phone>86-0351-5661145</phone>
      <email>yangbxys@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hongyan Tian, MD</last_name>
      <phone>86-029-85252580</phone>
      <email>tianhhyy@mail.xjtu.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xi'an NO.3 Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kang Cheng, MD</last_name>
      <phone>86-029-61895566</phone>
      <email>chengkang2009@foxmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>028</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaoping Chen, MD</last_name>
      <phone>86-028-85422114</phone>
      <email>chenxp13@aliyun.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>0571</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lijiang Tang, MD</last_name>
      <phone>86-0571-87987373</phone>
      <email>lxw_76@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2017</study_first_submitted>
  <study_first_submitted_qc>March 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2017</study_first_posted>
  <last_update_submitted>March 14, 2017</last_update_submitted>
  <last_update_submitted_qc>March 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences, Fuwai Hospital</investigator_affiliation>
    <investigator_full_name>Xiongjing Jiang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>renal artery stenosis</keyword>
  <keyword>balloon angioplasty</keyword>
  <keyword>stents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Renal Artery Obstruction</mesh_term>
    <mesh_term>Hypertension, Renovascular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

